Cerexa

Cerexa developed hospital-based anti-infective therapies for the treatment of patients with serious, life-threatening infections. Formed in the spring of 2005 as a spin-out from Peninsula Pharmaceuticals, it was sold to Forest Laboratories in 2007 for nearly $500 million. In 2010, the FDA approved its lead product, TeflaroTM (ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms. No Pappas Ventures portfolio company has progressed more rapidly from company creation to exit to FDA product approval.

Cerexa

Oakland, CA

12.14.2006
Cerexa to be acquired by Forest Laboratories for $480 million plu…

Read More

11.01.2006
Cerexa expands portfolio of novel anti-infective therapies throug…

Read More